Saturday, 20 April 2024
Apellis Pharmaceuticals Inc.
-
Overlay
-
Indicators
-
Settings
-
Period
04:22 | 18/3/18
Frisco Fastball
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has 0.00% since March 18, 2017 and is . It has underperformed by 16.70% the S&P500.
more»
03:37 | 18/3/18
The Lincolnian Online
Apellis Pharmaceuticals logo Shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports.
more»
00:36 | 18/3/18
The Ledger Gazette
News coverage about Apellis Pharmaceuticals (NASDAQ:APLS) has trended somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time.
more»
03:44 | 17/3/18
Stocks Gallery
In recent trading day Celldex Therapeutics, Inc. (CLDX) stock showed the move of -2.35% with the closing price of $2.49.
more»
09:15 | 16/3/18
Frisco Fastball
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases.
more»
08:52 | 15/3/18
BZ Weekly
More notable recent Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news were published by: Globenewswire.com which released: “Apellis Pharmaceuticals Announces Closing of its Initial Public Offering” on November 13, 2017, also Globenewswire.
more»
00:26 | 15/3/18
Post Analyst
Apellis Pharmaceuticals, Inc. is maintained at an average outperform rating by 4 stock analysts, and there are at least 4.43% of shares outstanding that are currently legally short sold.
more»
18:15 | 13/3/18
The Ledger Gazette
Apellis Pharmaceuticals logo Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases.
more»
06:48 | 13/3/18
The Ledger Gazette
Apellis Pharmaceuticals logo Sectoral Asset Management Inc acquired a new position in shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission ...
more»
07:00 | 6/3/18
Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) presented “updated” data from their FILLY trial at the 2018 Macula Society in late February (slides).
more»